Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 1:21 AM
Ignite Modification Date:
2025-12-25 @ 11:30 PM
NCT ID:
NCT00645593
Group ID:
EG001
Title:
Arm 2, Cetuximab, Gemcitabine and Cisplatin
Description:
Gemcitabine, Cisplatin and Cetuximab: Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle. Gemcitabine will be administered intravenously at a dose of 800 mg/m2 on Days 1, 8 and 15 of cycle. Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
Deaths Number Affected:
None
Deaths Number At Risk:
None
Serious Number Affected:
36
Serious Number At Risk:
60
Other Number Affected:
60
Other Number At Risk:
60
Study:
NCT00645593
Results Section:
NCT00645593
Adverse Events Module:
NCT00645593